>>Signaling Pathways>> Cell Cycle/Checkpoint>> Microtubule/Tubulin>>Valecobulin hydrochloride

Valecobulin hydrochloride (Synonyms: CKD-516 hydrochloride)

Catalog No.GC39177

발레코불린 염산염(CKD-516 염산염)은 S516의 발린 전구약물이자 혈관 교란제(VDA)입니다. Valecobulin hydrochloride는 쥐 및 인간 고형 종양에 대해 현저한 항종양 활성을 갖는 강력한 β-튜불린 중합 억제제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Valecobulin hydrochloride Chemical Structure

Cas No.: 1240321-53-2

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$409.00
재고 있음
5mg
US$324.00
재고 있음
10mg
US$510.00
재고 있음
50mg
US$1,530.00
재고 있음
100mg
US$2,086.00
재고 있음
200mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Valecobulin hydrochloride (CKD-516 hydrochloride) is a valine prodrug of S516 and a vascular disrupting agent (VDA). Valecobulin hydrochloride is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors[1][2].

[1]. Lee J, et al. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem. 2010 Sep 9;53(17):6337-54. [2]. Joo I, et al. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology. 2014 Aug;272(2):417-26.

리뷰

Review for Valecobulin hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Valecobulin hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.